KADCYLA 160 MG
TRASTUZUMAB EMTANSINE : 160 MG · DIN 02473224 · HOFFMANN-LA ROCHE LIMITED
Health Canada status: MARKETED
What is KADCYLA?
KADCYLA 160 MG contains TRASTUZUMAB EMTANSINE : 160 MG. It is listed in the Health Canada Drug Product Database under DIN 02473224, held by HOFFMANN-LA ROCHE LIMITED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 24-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is KADCYLA used for?
Kadcyla (trastuzumab emtansine for injection) monotherapy is indicated for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within 6 months of completing adjuvant therapy. Kadcyla monotherapy is indicated for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02473224 |
|---|---|
| Brand name | KADCYLA |
| Generic / active ingredient | TRASTUZUMAB EMTANSINE : 160 MG |
| Manufacturer | HOFFMANN-LA ROCHE LIMITED |
| Strength | 160 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01FD03 TRASTUZUMAB EMTANSINE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Oct-2018 |
| Original market date | 2018-10-24 00:00:00 |
How is it stored and handled?
Store reconstituted Kadcyla at 2-8ºC; discard unused Kadcyla after 24 hours. If not used immediately, the infusion can be stored for up to 24 hours in a refrigerator at 2-8°C. The infusion cannot be frozen or shaken during storage.
How is it supplied?
100 mg single-use vial, 160 mg single-use vial
What can be used instead?
Other Canadian products sharing ATC code L01FD03 TRASTUZUMAB EMTANSINE. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| KADCYLA | 100 MG | POWDER FOR SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02412365 |
Who else supplies TRASTUZUMAB EMTANSINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRASTUZUMAB EMTANSINE appears in 397 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.